Condition: Advanced Solid Tumor · Metastatic Solid Tumor · Non-small Cell Lung Cancer (NSCLC) · Sponsor: GI Innovation, Inc.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
This description comes directly from the study's public registry record.
Seunghwan Shin, M.D. · +82-2-404-2003 · clinical-108@gi-innovation.com
Always discuss trial participation with your own doctor first.
| Yonsei University Health System, Severance Hospital | Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07172802